Equities research analysts expect that Dova Pharmaceuticals Inc (NASDAQ:DOVA) will report sales of $5.18 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Dova Pharmaceuticals’ earnings. The highest sales estimate is $7.42 million and the lowest is $3.00 million. Dova Pharmaceuticals reported sales of $4.58 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 13.1%. The firm is scheduled to issue its next earnings report on Thursday, August 8th.
On average, analysts expect that Dova Pharmaceuticals will report full year sales of $29.13 million for the current fiscal year, with estimates ranging from $23.00 million to $33.90 million. For the next fiscal year, analysts anticipate that the business will report sales of $90.02 million, with estimates ranging from $55.37 million to $120.31 million. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Dova Pharmaceuticals.
Dova Pharmaceuticals (NASDAQ:DOVA) last posted its earnings results on Tuesday, May 7th. The company reported ($0.58) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.68) by $0.10. The company had revenue of $4.00 million for the quarter, compared to the consensus estimate of $3.46 million. Dova Pharmaceuticals had a negative return on equity of 87.20% and a negative net margin of 521.67%.
DOVA opened at $10.92 on Monday. The company has a current ratio of 4.46, a quick ratio of 5.51 and a debt-to-equity ratio of 0.20. The firm has a market cap of $290.23 million, a price-to-earnings ratio of -4.20 and a beta of 2.06. Dova Pharmaceuticals has a one year low of $5.62 and a one year high of $35.33.
In related news, Director Paul B. Manning acquired 68,000 shares of Dova Pharmaceuticals stock in a transaction dated Thursday, March 7th. The shares were acquired at an average cost of $7.48 per share, for a total transaction of $508,640.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 60.30% of the stock is owned by corporate insiders.
Large investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its position in shares of Dova Pharmaceuticals by 2.5% in the third quarter. Vanguard Group Inc. now owns 619,604 shares of the company’s stock valued at $12,993,000 after acquiring an additional 14,985 shares in the last quarter. Broadfin Capital LLC purchased a new stake in shares of Dova Pharmaceuticals in the fourth quarter valued at $2,667,000. BlackRock Inc. lifted its position in shares of Dova Pharmaceuticals by 0.8% in the third quarter. BlackRock Inc. now owns 1,154,232 shares of the company’s stock valued at $24,204,000 after acquiring an additional 9,312 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in shares of Dova Pharmaceuticals by 14,705.9% in the fourth quarter. PNC Financial Services Group Inc. now owns 5,034 shares of the company’s stock valued at $38,000 after acquiring an additional 5,000 shares in the last quarter. Finally, Teachers Advisors LLC lifted its position in shares of Dova Pharmaceuticals by 19.8% in the third quarter. Teachers Advisors LLC now owns 21,561 shares of the company’s stock valued at $452,000 after acquiring an additional 3,556 shares in the last quarter. Institutional investors and hedge funds own 31.10% of the company’s stock.
Dova Pharmaceuticals Company Profile
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure.
See Also: Buyback For Investors Defined
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.